These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37920464)

  • 41. Subunit vaccine raised against the SARS-CoV-2 spike of Delta and Omicron variants.
    Feng S; Fan Z; Zhou K; Ma S; Liang M; Zhang H; Xie Y; Ha Z; Jin N; Lu H
    J Med Virol; 2023 Oct; 95(10):e29160. PubMed ID: 37822266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
    Bisht H; Roberts A; Vogel L; Bukreyev A; Collins PL; Murphy BR; Subbarao K; Moss B
    Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6641-6. PubMed ID: 15096611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
    Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
    Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Single MVA-SARS-2-ST/N Vaccination Rapidly Protects K18-hACE2 Mice against a Lethal SARS-CoV-2 Challenge Infection.
    Clever S; Limpinsel L; Meyer Zu Natrup C; Schünemann LM; Beythien G; Rosiak M; Hülskötter K; Gregor KM; Tuchel T; Kalodimou G; Freudenstein A; Kumar S; Baumgärtner W; Sutter G; Tscherne A; Volz A
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity.
    Fluckiger AC; Ontsouka B; Bozic J; Diress A; Ahmed T; Berthoud T; Tran A; Duque D; Liao M; McCluskie M; Diaz-Mitoma F; Anderson DE; Soare C
    Vaccine; 2021 Aug; 39(35):4988-5001. PubMed ID: 34304928
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
    Lien CE; Kuo TY; Lin YJ; Lian WC; Lin MY; Liu LT; Cheng J; Chou YC; Chen C
    Clin Infect Dis; 2022 Jun; 74(11):1899-1905. PubMed ID: 34739037
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model.
    Langel SN; Johnson S; Martinez CI; Tedjakusuma SN; Peinovich N; Dora EG; Kuehl PJ; Irshad H; Barrett EG; Werts AD; Tucker SN
    Sci Transl Med; 2022 Aug; 14(658):eabn6868. PubMed ID: 35511920
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
    Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
    J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters.
    de Swart RL; de Leeuw OS; Oreshkova N; Gerhards NM; Albulescu IC; Vreman S; Gonzales JL; Maas R; van Kuppeveld FJM; Soema P; Bosch BJ; Peeters BPH
    Vaccine; 2022 Aug; 40(33):4676-4681. PubMed ID: 35820941
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.
    Mayer L; Weskamm LM; Fathi A; Kono M; Heidepriem J; Krähling V; Mellinghoff SC; Ly ML; Friedrich M; Hardtke S; Borregaard S; Hesterkamp T; Loeffler FF; Volz A; Sutter G; Becker S; Dahlke C; Addo MM
    NPJ Vaccines; 2024 Jan; 9(1):20. PubMed ID: 38278816
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
    Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
    Front Immunol; 2022; 13():836745. PubMed ID: 35693788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
    Lien CE; Lin YJ; Chen C; Lian WC; Kuo TY; Campbell JD; Traquina P; Lin MY; Liu LT; Chuang YS; Ko HY; Liao CC; Chen YH; Jan JT; Ma HH; Sun CP; Lin YS; Wu PY; Wang YC; Tao MH; Lin YL
    Sci Rep; 2021 Apr; 11(1):8761. PubMed ID: 33888840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
    Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W
    J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
    Berry C; Pavot V; Anosova NG; Kishko M; Li L; Tibbitts T; Raillard A; Gautheron S; Cummings S; Bangari DS; Kar S; Atyeo C; Deng Y; Alter G; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Commun Med (Lond); 2023 May; 3(1):75. PubMed ID: 37237062
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Hashimoto M; Nagata N; Homma T; Maeda H; Dohi K; Seki NM; Yoshihara K; Iwata-Yoshikawa N; Shiwa-Sudo N; Sakai Y; Shirakura M; Kishida N; Arita T; Suzuki Y; Watanabe S; Asanuma H; Sonoyama T; Suzuki T; Omoto S; Hasegawa H
    Vaccine; 2022 Jul; 40(31):4231-4241. PubMed ID: 35691872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.